An anti-Factor D antibody or Factor D-binding fragment thereof, comprising: (i) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:5, wherein CDR1 is defined by SEQ ID NO:16, CDR2 is defined by SEQ ID NO:17, and CDR3 is defined by SEQ ID NO:18; and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:6, wherein CDR1 is defined by SEQ ID NO:13; CDR2 is defined by SEQ ID NO:14; and CDR3 is defined by SEQ ID NO:15; (ii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:7, wherein CDR1 is defined by SEQ ID NO:16, CDR2 is defined by SEQ ID NO:17, and CDR3 is defined by SEQ ID NO:19; and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:8, wherein CDR1 is defined by SEQ ID NO:13, CDR2 is defined by SEQ ID NO:14, and CDR3 is defined by SEQ ID NO:20; (iii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:9, wherein CDR1 is defined by SEQ ID NO:16, CDR2 is defined by SEQ ID NO:21, and CDR3 is defined by SEQ ID NO:22; and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:10, wherein CDR1 is defined by SEQ ID NO:23, CDR2 is defined by SEQ ID NO:14, and CDR3 is defined by SEQ ID NO:20; or (iv) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:11, wherein CDR1 is defined by SEQ ID NO:16, CDR2 is defined by SEQ ID NO:24, and CDR3 is defined by SEQ ID NO:19; and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:12, wherein CDR1 is defined by SEQ ID NO:25, CDR2 is defined by SEQ ID NO:14, and CDR3 is defined by SEQ ID NO:20, wherein regions of the light chain variable domain and heavy chain variable domain outside the CDR regions are framework regions, and wherein at least one framework region comprises none, one, two or three amino acid substitutions. (i) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:5, wherein CDR1 is defined by SEQ ID NO:16, CDR2 is defined by SEQ ID NO:17, and CDR3 is defined by SEQ ID NO:18; and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:6, wherein CDR1 is defined by SEQ ID NO:13; CDR2 is defined by SEQ ID NO:14; and CDR3 is defined by SEQ ID NO:15; (ii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:7, wherein CDR1 is defined by SEQ ID NO:16, CDR2 is defined by SEQ ID NO:17, and CDR3 is defined by SEQ ID NO:19; and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:8, wherein CDR1 is defined by SEQ ID NO:13, CDR2 is defined by SEQ ID NO:14, and CDR3 is defined by SEQ ID NO:20; (iii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:9, wherein CDR1 is defined by SEQ ID NO:16, CDR2 is defined by SEQ ID NO:21, and CDR3 is defined by SEQ ID NO:22; and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:10, wherein CDR1 is defined by SEQ ID NO:23, CDR2 is defined by SEQ ID NO:14, and CDR3 is defined by SEQ ID NO:20; or (iv) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:11, wherein CDR1 is defined by SEQ ID NO:16, CDR2 is defined by SEQ ID NO:24, and CDR3 is defined by SEQ ID NO:19; and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:12, wherein CDR1 is defined by SEQ ID NO:25, CDR2 is defined by SEQ ID NO:14, and CDR3 is defined by SEQ ID NO:20,